Several other research analysts have also weighed in on TRVN. Zacks Investment Research lowered Trevena from a buy rating to a hold rating and set a $2.00 price target on the stock. in a research report on Saturday, January 20th. HC Wainwright upped their price target on Trevena to $7.00 and gave the company a buy rating in a research report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $7.06.
Shares of Trevena stock opened at $1.72 on Thursday. The stock has a market capitalization of $115.16, a price-to-earnings ratio of -1.41 and a beta of -0.61. The company has a current ratio of 3.71, a quick ratio of 3.71 and a debt-to-equity ratio of 0.45. Trevena has a 52-week low of $1.34 and a 52-week high of $3.98.
Large investors have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in Trevena during the fourth quarter valued at $130,000. American Century Companies Inc. acquired a new position in Trevena during the fourth quarter valued at $135,000. California State Teachers Retirement System raised its position in Trevena by 0.5% during the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 500 shares during the period. Bourgeon Capital Management LLC raised its position in Trevena by 59.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 51,300 shares during the period. Finally, Virtu Financial LLC raised its position in Trevena by 1,546.1% during the fourth quarter. Virtu Financial LLC now owns 191,701 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 180,055 shares during the period. 50.47% of the stock is currently owned by hedge funds and other institutional investors.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.